News Releases
Jun 7 2006
Peregrine's Bavituximab Shows Promising Anti-Viral Activity and Signs of Prolonged Anti-Viral Effect in Single Dose Monotherapy HCV Trial
May 24 2006
Peregrine Pharmaceuticals' Bavituximab Shows Potential Activity Against Avian Flu in Initial Testing
Apr 25 2006
Peregrine Pharmaceuticals Announces New DOD Grant to Study Bavituximab (Tarvacin) in Breast Cancer
Apr 24 2006
Peregrine Pharmaceuticals Transitions Tarvacin Name to Official Generic Name Bavituximab
Apr 6 2006
Peregrine Pharmaceuticals Announces $4.9 Million Equity Financing
Apr 3 2006
Preclinical Studies Presented at AACR Meeting Show Potential of Peregrine's Tarvacin(TM) Plus Radiation or Chemotherapy to Increase Survival in Resistant Breast Cancer and Brain Cancer
Mar 31 2006
Peregrine Pharmaceuticals Files Shelf Registration Statement
Mar 17 2006
Peregrine Pharmaceuticals Adopts Stockholder Rights Agreement
Mar 13 2006
Peregrine Pharmaceuticals Reports Fiscal Year 2006 Third Quarter Results
Mar 7 2006
Peregrine Pharmaceuticals to Announce Third Quarter FY 2006 Financial Results on March 13, 2006